Back

Breye plans 2027 Phase 2 trial of oral danegaptide for NPDR

Verifying
  • Breye published a paper on oral danegaptide’s potential treatment of NPDR.
  • Danegaptide protected the inner blood-retina barrier in preclinical and Phase 1b research.
  • Breye plans a randomized Phase 2 NPDR trial beginning in 2027.
The information on this website is generated using AI and we cannot guarantee its accuracy. Please use it as reference information only.
Breye plans 2027 Phase 2 trial of oral danegaptide for NPDR - CoinPost Terminal